KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.

Everett H Meyer, Amandeep Salhotra, Arpita P Gandhi, Jeremy Pantin, Sagar S Patel, Rasmus T Hoeg, Alexandra Gomez-Arteaga, Rawan Faramand, Roni Tamari, Edmund K Waller, Satyajit Kosuri, Antonio M Jimenez Jimenez, Jennifer Holter-Chakrabarty, Bhagirathbhai Dholaria, Yi-Bin Chen, Betty K Hamilton, John Magenau, Alireza Eghtedar, Joshua M Murray, Anna Pavlova, Nathaniel B Fernhoff, James Scott McClellan, M Scott Killian, Ai Li, Robert S Negrin, Caspian Oliai

Blood 147(11) 1168-1177

PMID41385341
PMCIDPMC13123417
DOI10.1182/blood.2025031313
发表日期2025-12-12
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

To prevent graft-versus-host disease (GVHD) in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT), a calcineurin inhibitor plus methotrexate is routinely used. Early phase studies suggested improved outcomes with Orca-T, an allogeneic T-cell immunotherapy that uses purified donor regulatory T cells to prevent GVHD with significantly less immunosuppression. This phase 3 trial randomized adult patients (N = 187) with acute leukemias or myelodysplastic syndrome undergoing myeloablative conditioning to receive either Orca-T with tacrolimus or a conventional allograft with tacrolimus and methotrexate (Tac/MTX), using granulocyte colony-stimulating factor-mobilized peripheral blood from HLA-matched donors. The primary end point was survival free from moderate-to-severe chronic GVHD (cGVHD; cGFS). Using a stratified log-rank test, cGFS was significantly higher in the Orca-T arm than in Tac/MTX (hazard ratio, 0.26; 95% confidence interval, 0.14-0.47; P< .001). One-year estimates were as follows: cGFS was 78.0% with Orca-T vs 38.4% with Tac/MTX; cumulative incidence of moderate-to-severe cGVHD was 12.6% with Orca-T and 44.0% with Tac/MTX (Gray test P< .001); overall survival was 93.9% with Orca-T vs 83.1% with Tac/MTX (P = .12); GVHD-free and relapse-free survival was 63.1% and 30.9% in the Orca-T and Tac/MTX arms (P< .001), respectively; nonrelapse mortality (NRM) was 3.4% with Orca-T vs 13.2% with Tac/MTX (P = .03). Orca-T met the primary end point of improved survival free from cGVHD compared with Tac/MTX prophylaxis and should be considered a new therapeutic option with low toxicity for GVHD prophylaxis. Moreover, significantly less toxicity was observed with Orca-T patients, including fewer serious infectious complications and less NRM. This trial was registered at www.clinicaltrials.gov as NCT05316701.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 2

Figure 2. Survival probabilities and the cumulative incidence of primary and secondary end point events. (A) The cGFS (the primary end point) after Orca-T or Tac/MTX prophylaxis over 1 year. The shaded areas indicate 95% simultaneous confidence bands. (B) The cumulative incidence of moderate-to-severe cGVHD over 1 year. (C) The OS probability over 1 year. (D) The survival free from grade 3 to 4 acute GVHD, moderate-to-severe cGVHD, or relapse (GRFS) over 1 year. For the estimates of the secondary end point events, 95% CIs for survival and cumulative incidence at 1 year (panels B-D) are provided, but they have not been adjusted for multiplicity and should not be used for hypothesis testing.

A

cGFS

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

cGVHD, moderate or severe

Figure 2 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

OS

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact曲线 2:flat topline artifact
查看结果
D

GRFS

Figure 2 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. CONSORT diagram detailing randomization, treatment, and follow-up. a Treatment was delayed due to severe acute respiratory syndrome coronavirus 2 infection. The patient subsequently received unmanipulated PBSCs with Tac/MTX. b Due to matched donor becoming unavailable. c As-treated population. d As-treated population, including the patient randomized to the Orca-T arm who received Tac/MTX and excludes the Haplo/PTCy patient. Haplo, haploidentical.
非 KM Figure
Figure 3Figure 3. Immunological associations with infection and treatment-related mortality. (A) CD4 + T-cell counts measured in fresh whole blood at scheduled visits posttransplant. The solid circles denote median values, whereas the shading indicates the 25th to 75th percentiles. (B) Treg frequencies shown in fresh whole blood collected 14 days after transplant from participants in the Orca-T and Tac/MTX arms. Treg frequencies are defined as the percentage of CD25 bright CD127 dim cells among the total CD3 + CD4 + lymphocytes. The boxes reveal the 25th, 50th, and 75th percentiles, whereas the whiskers denote the 10th and 90th percentiles. Median values are provided within the boxes. The P value was derived from the rank sum test. (C) The cumulative incidence of grade 3 infections in each treatment arm is depicted. Infections were graded based on the BMT CTN Manual of Procedures scoring. (D) Primary causes of death are shown for each treatment arm. The causes of NRM are indicated by the hatched fills.
非 KM Figure